CSL Behring
CSL Behring is a global leader in the plasma protein biotherapeutics industry. They research, develop, manufacture and market biotherapies that are used to treat serious and rare conditions. Users of Their therapies rely on them for their quality of life and, in many cases, for life itself. Their commitment to saving lives and improving the quality of life for people with serious and rare conditions is evident in everything They do. Whether They are manufacturing and marketing safe and effective products or researching and developing innovative biotherapies, They are first and foremost focused on fulfilling Their customers’ needs.
Industries
Nr. of Employees
Very Large (1000+)
CSL Behring
King Of Prussia, Pennsylvania, United States, North America
Products
AFSTYLA
A recombinant antihemophilic factor used for the treatment of Hemophilia A.
HEMGENIX
A gene therapy product for Hemophilia B, administered through intravenous infusion.
IDELVION
A coagulation factor IX albumin fusion protein designed for the treatment of Hemophilia B.
Hizentra
An immune globulin subcutaneous solution for treating primary immunodeficiency.
Privigen
An intravenous immune globulin for the treatment of primary immunodeficiency and other immune disorders.
Plasma Collection
CSL Plasma operates plasma collection centers to support the manufacturing of plasma-derived therapies.
AFSTYLA
A recombinant antihemophilic factor used for the treatment of Hemophilia A.
HEMGENIX
A gene therapy product for Hemophilia B, administered through intravenous infusion.
IDELVION
A coagulation factor IX albumin fusion protein designed for the treatment of Hemophilia B.
Hizentra
An immune globulin subcutaneous solution for treating primary immunodeficiency.
Privigen
An intravenous immune globulin for the treatment of primary immunodeficiency and other immune disorders.
Plasma Collection
CSL Plasma operates plasma collection centers to support the manufacturing of plasma-derived therapies.